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Clinical Observations 
 
Effects of Jingyuankang Capsules (㊒ܗᒋ㛊ಞ) on Leukocyte Level in 
AIDS Patients 
 
JIANG Shi-qing 㩟຿॓ 1, SUN Hong-xin ᄭᅣᮄ 2, XU Ying-min ᕤ㣅ᬣ 1, JIANG Yan-ling 㩟㡇⦆ 2,  
PEI Jun-wen 㻈֞᭛ 3, and WANG Hong-ling ⥟㑶⦆ 1 
 
Objective: To observe the therapeutic effects of Jingyuankang capsules (㊒ܗᒋ㛊ಞ) for leukopenia in AIDS 
patients. 
Methods: In this randomized double-blind trial, 58 patients orally took Jingyuankang capsule, analog Leucogen 
tablet and the HAART (highly active anti-retroviral therapy) drugs, and the other 58 patients took Leucogen tablet, 
analog Jingyuankang capsule and the HAART drugs all for 6 months, during which the peripheral hemogram was 
periodically examined to observe the therapeutic effects of Jingyuankang capsule for leukopenia of the AIDS 
patients.   
Results: With good therapeutic effect for leukopenia of the AIDS patients, Jingyuankang capsule can enhance 
leukocyte level as effective as Leucogen tablet in treating grade ȱ and grade Ċ leukopenia, and more effectively 
than Leucogen tablet in treating grade ċleukopenia. No toxic side-effects and adverse reactions were found 
during the treatment and in the follow-up visit. 
Conclusion: Jingyuankang capsule can effectively treat leukopenia of the AIDS patients. 
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The HAART (highly active anti-retroviral therapy) drugs 
now used in China are all imitations of the drugs early 
developed abroad with severe toxic side-effects, mainly 
manifested by leukopenia due to arrest of bone marrow. 
The patients often stop taking the drugs because of the 
intolerable toxic side-effects, thus seriously influencing 
therapeutic effect. At present, there are no drugs special 
for leukopenia of AIDS patients in the world. Therefore, 
it is of important significance to develop drugs for 
treating and preventing leucopenia of the AIDS patients. 
Based on the previous study, Jingyuankang capsule (㊒
ܗᒋ㛊ಞ), which has obvious therapeutic effect for 
arrest of bone marrow caused by radiotherapy and 
chemotherapy of cancer1, was used to treat leucopenia of 
116 AIDS patients in Shangcai County, Henan Province 
in a period clinical from January 2006 to June 2007. now 
the authors reported as follows.  
METHODS 
General Data 
The 116 AIDS patients, conforming to the Standards for 
Diagnosing and the Principles for Treating HIV/AIDS 
promulgated by the Health Ministry of China, were 
randomly divided into two groups using SPSS 13.0 
random number program. 
The patients, all definitely diagnosed in AIDS general 
survey among the high risk people in Henan Province in 
2003, were infected with HIV (short for human 
immunodeficiency virus) via blood supply from 1989 to 
1994. They voluntarily took part in the trial (signing a 
consent after being informed about the facts, and the trial 
was permitted by Health Care Ethics Committee) and 
were randomly divided into two groups. Fifty-eight 
patients were in the treatment group, aged 26–62, 42.4 
on the average; the 58 patients were in the control group, 
aged 29 to 62, 43.6 on the average, both with a ratio 
about 1:2 between men and women. All the patients of 
the two groups had taken HAART drugs before the trial 
for 4–36 months. 1 
There were no significant difference between the two 
groups in the score of symptoms and signs, peripheral 
hemogram, Karnofsky score, body weight, and CD4+, 
hence comparable. 
Case Selection 
1. Diagnostic Standards: 
Standards for diagnosing HIV/AIDS are drawn up 
according to the Standards for Diagnosing and the 
Principles for Treating HIV/AIDS promulgated by the 
Health Ministry of China.2 
Standards for classifying the toxic side-effects of 
HAART drugs are drawn up in reference to the Standards 
for Grading Toxic Side-effects of Anti-cancer Drugs 
promulgated by WHO.3 
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Standards for diagnosing leukopenia are worked out in 
reference to the Standards for Diagnosing Hemotopathy 
and Evaluating the Therapeutic Effect compiled by 
ZHANG Zhi-nan.4 
Standards for diagnosing TCM syndromes are worked 
out according to the Instructive Principles for Clinical 
Researches of New TCM Drugs compiled by ZHENG 
Xiao-yu.5 
Standards for classifying and quantifying the symptoms 
and signs are drawn up in reference to the Instruction 
Principles for Clinical Researches of New TCM Drugs 
complied by ZHENG Xiao-yu and the TCM Technical 
Plan (Trial) Implemented in 5 Provinces for Clinical 
Treatment of AIDS promulgated by the State TCM 
Administration.5,6 
Standards for classifying the quality of life are drawn up 
according to the Karnofskys Scale quoted from Practical 
Internal Medicine for Tumors complied by ZHOU Ji- 
chang.3 
2. Standards for case inclusion: 
The patients conforming to the standards for diagnosing 
HIV/AIDS in Western medicine have taken HAART 
drugs. The patients with peripheral blood WBC <4.0 × 
109/L but 1.0 × 109/L, neutrophilic granulocyte 0.5 × 
109 /L, in men Hb <120 g/L but 80g/L, in women Hb 
<100 g/L but 65 g/L, and PLT <100 × 109/L but 50 × 
109/L. The patients conform to the standards for 
diagnosing TCM syndromes with deficiency of both the 
spleen and kidney. The patients, aged 18 but 65, 
predicted to survive for 6 months. The Karnofsky’s score 
60. The patients have signed a consent after being 
informed about the facts. 
3. Standards for case exclusion: 
The patients have severe diseases of the heart (Grade 
ċ/Č), liver (ALT 200 μ/L), kidney and blood. The 
patients do not conform to inclusive standards. The 
patients have severe mental disease or dementia. The 
patients have taken drugs for less than 6 months. The 
patients with malignant tumors. The patients have one or 
more active opportunistic infections such as 
pneumocystis carinii pneumonia, herpes zoster and 
pulmonary tuberculosis. The patients have severe 
symptoms of the whole body, such as inability to take 
care of their daily life, faint or coma, headache like 
epileptic attack, and cachexia. The patients can not stop 
excessive drinking. Women in the period of pregnancy or 
lactation. 
4. Standards for exfoliation and rejection: 
Standards for exfoliation: 1) The patients voluntarily quit 
from the trial. 2) The patients have obvious adverse 
reactions closely related to the medication. 3) The 
patients have severe complications during the trial.  
Standards for rejection: 1) The patients do not take drugs 
according to the instruction or do not come for 
reexamination in time. 2) The patients additionally take 
other drugs with similar actions, affecting evaluation of 
therapeutic effects. 3) The patients not conforming to the 
inclusive standards are found after taking part in the trial. 
Group and Medication 
For treatment group: 1) HAART: a) AZT: 300 mg, twice 
one day, oral (note: AZT will be replaced with D4T when 
WBC <2.0×109/L and Hb <90 g/L). b) DDI: 250 mg, Bid, 
Po for body weight 60 kg; and 167 mg, twice one day, 
oral for body weight <60 kg. c) NVP: 200 mg, once one 
day (14 days later, once/d is replaced with twice/d). 2) 5 
Jingyuankang capsules, three times one day, oral. 2 
analog Leucogen tablets, three times one day, oral.  
 
For control group: 1) HAART: the same as in treatment 
group’s. 2) 2 Leucogen tablets (20 mg), three times one 
day, oral. Five analog Jingyuankang capsules, three times 
one day, oral. 
The treatment course: the patients take drugs for 6 
months in 2 courses of treatment with 3 months as one 
therapeutic course. 
Additional use of drugs: 1) For mild opportunistic 
infection, additional drugs should be used according to 
relevant rules. However, it should be avoided to use the 
drugs influencing peripheral hemogram. 2) For other 
complicated diseases, drugs should be given according to 
medical routine. 3) It is prohibited to use the drugs 
possibly influencing peripheral hemogram. 
The Indexes Observed 
Peripheral blood routine (including leukocyte, granu- 
locyte, lymphocyte, hemoglobin, blood platelet and red 
blood cell) should be examined once every half a month.  
Criteria for Evaluating Therapeutic Effects 
Markedly effective: The leukocyte level returned to 
normal (4.0×109/L) in 2 consecutive examinations. 
Effective: The leukocyte level raised by 100% or to 
3.0×109/L, and granulocytes >1.5×109/L in several 
consecutive examinations. Ineffective: no obvious 
increase in leukocyte level after treatment. 
Statistical Analysis 
SPSS13.0 software is used for the statistical analysis.  
Bilateral examination is used for all the statistical 
examinations. P<0.05 will be regarded as having 
statistical difference. Average value ± standard difference 
is used to statistically describe numerical variables,and t 
tests were performed.Frequency is used to statistically 
describe classified variables,and rank test was used. 
RESULTS 
Through 6 months of systematic observation, no patient 
died and one case exfoliated (accounting for 0.8% of the 
116 patients). Peripheral hemogram in the patients of the 
2 groups improved in varying degrees. 
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Comparison of the Therapeutic Effects 
Changes in WBC of the patients before and after 
treatment in the 2 groups: Among the 57 patients in the 
treatment group, marked effect was found in 35 cases, 
effectiveness in 19 cases and ineffectiveness in 3 cases, 
with a effective rate of 94.7%. Among the 58 patients in 
the control group, marked effect was found in 26 cases, 
effectiveness in 20 cases and ineffectiveness in 10 cases 
with a effective rate of 82.8%. There was a significant 
difference in therapeutic effects between the 2 groups 
(P<0.05, Table 1). 
Comparison of the Leukocyte Levels of the Patients 
before and after Treatment  
According to the leukocyte levels of patients before 
treatment and the WHO standards for classifying toxic 
side-effects of drugs (gradeĉ: WBC 3.0–3.9, grade Ċ: 
2.0–2.9, grade ċ: 1.0–1.9), the 2 groups were divided 
respectively into 3 subgroups of grade, Ċ and ċ 
leukopenia for comparing the change of WBC before and 
after treatment. 
Comparison of the leukocyte levels in patients with 
grade ȱ  leukopenia before and after treatment showed 
that there was an obvious difference in both groups, 
indicating that both the drugs can enhance the leukocyte 
level (P<0.05). However, there was no obvious 
difference (P>0.05) before treatment (0 month) and after 
treatment (6 months) between the two subgroups, 
indicating that the two drugs have similar effect on 
enhancing leukocyte level for grade ȱ leucopenia (Table 
2). 
Table 1. Comparison of changes in WBC of the patients before and after treatment between the 2 groups (cases)    
Group Cases Markedly effective Effective Ineffective Effective rate (%) 
Treatment group 57 35 19 3 94.7 
Control group 58 26 22 10 82.8 
Note: Z=2.096, P<0.05. 
Table 2. Comparison of the leukocyte levels in patients with grade ȱ leukopenia before and after treatment in the two 
groups ( x ±s, ×109/L) 
Group Cases 0 month 6 months 
Treatment group 34 3.41±0.31Ÿ 5.22±1.53 
Control group 36  3.53±0.30Ÿ*  4.85±1.95* 
Notes: ŸP<0.05 compared with that of 6 months; *P>0.05 compared with the treatment group. 
Comparison of the leukocyte levels in patients with 
grade Ċ leukopenia before and after treatment showed 
that there was an obvious difference in both groups, 
indicating that both the drugs can enhance leukocyte 
level (P<0.05). However, there was no obvious 
difference (P>0.05) before treatment (0 month) and after 
treatment (6 months) between the two subgroups, 
indicating that the two drugs have a similar effect on 
enhancing leukocyte level for grade Ċ leucopenia, as 
shown in Table 3. 
There were 4 patients with grade ċ leukopenia before 
treatment in both the two groups. After treatment, the 
leukocyte level returned to normal in all the 4 patients of 
the treatment group but only in one patient of the control 
group, showing that Jingyuankang capsule has better 
therapeutic effect than the contrast drug for grade ċ 
leucopenia, as shown in Table 4. Statistical analysis was 
not made because of few cases involved in the test. 
Toxic side-effects and adverse reactions caused by 
Jingyuankang capsules were not found during the 
treatment and in the follow-up visit. 
Table 3. Comparison of the leukocyte levels in patients with grade Ċleukopenia before and after treatment in the two 
groups ( x ±s, ×109/L) 
Group Cases 0 month 6 months 
Treatment group 19 2.52±0.29Ÿ 5.84±1.39 
Control group 18  2.60±0.27Ÿ*  4.90±1.89* 
Notes: ŸP<0.05 compared with that of 6 months; *P>0.05 compared with the treatment group.  
Table 4. Comparison of the leukocyte levels in patients 
with grade ċ leucopenia before and after treatment in 
the two groups 
Group The coding number 0 month 6 months 
7 1.5 6.4 
67 1.4 4.7 
68 1.8 4.8 
Treatment group  
100 1.9 7.9 
9 1.1 7.5 
30 1.9 3.7 
48 1.6 3.9 
Control group 
82 1.7 1.7 
CONCLUSION 
Jingyuankang capsule can obviously enhance the 
leukocyte level in patients with leukopenia caused by 
AIDS and HAART. The total therapeutic effect is better 
than that of Leucogen tablet. 
Jingyuankang capsule can enhance the leukocyte level as 
effective as Leucogen tablet in treating patients with 
grade ȱ and Ċleucopenia and more effectively than 
Leucogen tablet in treating grade ċ leucopenia, 
preliminarily showing the good therapeutic effect of 
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Jingyuankang capsule for severe leukopenia. Because of 
few cases involved in the test, the therapeutic effect of 
Jingyuankang capsule remains to be further studied. 
DISCUSSION 
All the similar researches in the past were completely 
separated from the pathogenic circumstances, that is to 
say, drugs were used for observation after radiotherapy 
and chemotherapy. Because of the specialty, AIDS can 
not be treated without HAART, so Jingyuankang capsule 
should be used together with HAART. The results from 
the present study shows that the more advantages of 
TCM can be reflected. 
The previous researches put the patients with WBC 
2.5×109/L under observation. We expanded the range to 
 1.0×109/L, making it much more difficult the research, 
but still obtained good therapeutic effect of TCM. 
The present study shows that Jingyuankang capsule, with 
good therapeutic effects, less toxic side-effects, and can 
improve the leukocyte level in AIDS patients, reduce the 
toxic side-effects of HAART, thus guarantee a smooth- 
going of the treatment.   
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